WO2023082820A1 - Marqueur pour le diagnostic d'un adénocarcinome pulmonaire et son application - Google Patents
Marqueur pour le diagnostic d'un adénocarcinome pulmonaire et son application Download PDFInfo
- Publication number
- WO2023082820A1 WO2023082820A1 PCT/CN2022/118708 CN2022118708W WO2023082820A1 WO 2023082820 A1 WO2023082820 A1 WO 2023082820A1 CN 2022118708 W CN2022118708 W CN 2022118708W WO 2023082820 A1 WO2023082820 A1 WO 2023082820A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lung adenocarcinoma
- phase
- metabolites
- diagnosing
- metabolic
- Prior art date
Links
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 title claims abstract description 93
- 201000005249 lung adenocarcinoma Diseases 0.000 title claims abstract description 93
- 238000003745 diagnosis Methods 0.000 title claims abstract description 38
- 239000003550 marker Substances 0.000 title claims abstract description 25
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims abstract description 46
- 230000002503 metabolic effect Effects 0.000 claims abstract description 45
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims abstract description 38
- QQHJDPROMQRDLA-UHFFFAOYSA-N hexadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCC(O)=O QQHJDPROMQRDLA-UHFFFAOYSA-N 0.000 claims abstract description 38
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 30
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 claims abstract description 23
- 238000012216 screening Methods 0.000 claims abstract description 22
- 238000012544 monitoring process Methods 0.000 claims abstract description 18
- XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 17
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims abstract description 16
- 229960002591 hydroxyproline Drugs 0.000 claims abstract description 16
- 239000002253 acid Substances 0.000 claims abstract description 15
- 229960003624 creatine Drugs 0.000 claims abstract description 15
- 239000006046 creatine Substances 0.000 claims abstract description 15
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 14
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 14
- 235000004279 alanine Nutrition 0.000 claims abstract description 14
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 14
- 239000004220 glutamic acid Substances 0.000 claims abstract description 14
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 8
- 239000002207 metabolite Substances 0.000 claims description 68
- 210000002966 serum Anatomy 0.000 claims description 25
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 20
- 201000005202 lung cancer Diseases 0.000 claims description 20
- 208000020816 lung neoplasm Diseases 0.000 claims description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 16
- 238000001514 detection method Methods 0.000 claims description 14
- 238000004949 mass spectrometry Methods 0.000 claims description 14
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-Phenylalanine Natural products OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 150000002500 ions Chemical class 0.000 claims description 8
- 238000002705 metabolomic analysis Methods 0.000 claims description 8
- 230000001431 metabolomic effect Effects 0.000 claims description 8
- 230000014759 maintenance of location Effects 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 238000001819 mass spectrum Methods 0.000 claims description 5
- 229960005190 phenylalanine Drugs 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 238000002552 multiple reaction monitoring Methods 0.000 claims description 4
- 238000007619 statistical method Methods 0.000 claims description 4
- 238000001269 time-of-flight mass spectrometry Methods 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 3
- 238000007477 logistic regression Methods 0.000 claims description 3
- 229960002429 proline Drugs 0.000 claims description 3
- 229930182821 L-proline Natural products 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000013211 curve analysis Methods 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 238000010239 partial least squares discriminant analysis Methods 0.000 claims description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims description 2
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 23
- 238000001574 biopsy Methods 0.000 abstract description 2
- 238000003384 imaging method Methods 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 230000005855 radiation Effects 0.000 abstract description 2
- 230000008733 trauma Effects 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 13
- 229960003767 alanine Drugs 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 6
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 6
- 229960002173 citrulline Drugs 0.000 description 6
- 235000013477 citrulline Nutrition 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000013062 quality control Sample Substances 0.000 description 6
- 230000006682 Warburg effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- NQNXERHVLXYXRO-UHFFFAOYSA-N Diacetylspermine Chemical compound Cl.Cl.CC(=O)NCCCNCCCCNCCCNC(C)=O NQNXERHVLXYXRO-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000005315 distribution function Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
- G01N30/724—Nebulising, aerosol formation or ionisation
- G01N30/7266—Nebulising, aerosol formation or ionisation by electric field, e.g. electrospray
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
Definitions
- the invention relates to the technical field of detection and diagnosis, in particular to a marker for lung adenocarcinoma diagnosis and its screening method and application.
- lung cancer is mainly divided into two types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
- NSCLC non-small cell lung cancer
- SCLC small cell lung cancer
- the proportion of non-small cell lung cancer is as high as 85% to 90%.
- NSCLC further includes lung adenocarcinoma, lung squamous cell carcinoma, and large cell carcinoma. Compared with small cell carcinoma, the growth and division of cancer cells are slower, and the spread and metastasis are relatively late.
- the most common subtype of lung cancer is lung adenocarcinoma.
- Clinically, non-small cell lung cancer is often diagnosed at an advanced stage. More than half of NSCLC patients die within 1 year after diagnosis, and the 5-year survival rate is less than 20%. However, the 5-year survival rate of patients with early lung cancer can be as high as 90%. Therefore, early diagnosis of lung cancer is an important method for lung cancer patients to obtain a good prognosis and reduce mortality.
- the means of clinical diagnosis of lung cancer mainly rely on ultrasound imaging and lung puncture.
- the sensitivity of ultrasound diagnosis is low, and lung puncture is harmful to the lungs of patients, which is risky and difficult to promote.
- many patients are not diagnosed until the decompensated stage of lung cancer.
- gene molecules can be used as markers for the diagnosis of lung cancer, but the sensitivity and specificity of single gene diagnosis need to be improved urgently.
- LDCT low-dose computed tomography
- Metabolomics is an emerging discipline after genomics and proteomics, and is an important part of systems biology. Metabolomics has developed and rapidly penetrated into many fields, and its purpose is to study the overall metabolic differences in biological systems by monitoring the levels of small molecule metabolites in biological fluids or tissues, and to find the relative relationship between metabolites and pathophysiological changes. The occurrence of tumors is bound to be accompanied by metabolic changes, but in the early stages, the changes of small molecule metabolites are very weak and not easy to be found (Pei-Hsuan, C., Ling, C., Kenneth, H. et al. Metabolic diversity in human non-small cell lung cancer cells. Molecular Cell. 2019, 76, 1-14.
- Lung cancer diagnostic biomarkers such as Mathe, E.A., Patterson, A.D., Haznadar, M. et al.
- Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer Res. 2014, 74:3259-3270. William, R.W.
- the metabolic marker obtained through screening has great clinical application value, and is especially suitable for the prediction and diagnosis of early lung cancer.
- the present invention adopts following technical scheme:
- the present invention provides a marker for diagnosing or monitoring lung adenocarcinoma, wherein the metabolic marker is at least selected from D-galactose, homocitrulline, N6-acetyl-L-lysine, 4-hydroxy-L - at least one of proline, hexadecanedioic acid, guanine, glutamic acid, creatine, alanine, kynuric acid.
- the metabolic marker is at least selected from D-galactose, homocitrulline, N6-acetyl-L-lysine, 4-hydroxy-L - at least one of proline, hexadecanedioic acid, guanine, glutamic acid, creatine, alanine, kynuric acid.
- the present invention provides a marker for diagnosing or monitoring lung adenocarcinoma
- the combination of metabolic markers is at least selected from D-galactose, homocitrulline, N6-acetyl-L-lysine, 4-hydroxy- At least one of L-proline, hexadecanedioic acid, and guanine.
- the marker combination is also selected from at least one of glutamic acid, creatine, alanine, and kynuric acid.
- the AUC value of the area under the ROC curve of a single metabolic marker in the present invention is 0.7-0.9.
- the performance of multiple metabolite groups is significantly better than that of a single metabolite, and the area under the ROC curve AUC value is 0.86-0.99, which can effectively diagnose patients with early lung adenocarcinoma.
- the present invention also provides a reagent product or kit, including the above-mentioned standard product of metabolic markers for early diagnosis or monitoring of lung adenocarcinoma.
- the reagent product or kit also includes solvents and/or internal standards for extracting and enriching the metabolic markers.
- the present invention also provides a method for screening metabolic markers for diagnosing or monitoring lung adenocarcinoma, comprising the following steps:
- the samples of the lung adenocarcinoma group and the serum samples of the healthy group were collected separately, and the TNM staging of the patients in the lung adenocarcinoma group included stage I, stage II, stage III, and stage IV;
- the screening criteria with a P value less than 0.05 were used to obtain candidate differential metabolites; the candidate differential
- the 10 metabolic markers screened by the present invention can effectively diagnose lung adenocarcinoma patients.
- the invention can realize the diagnosis of lung adenocarcinoma only by taking blood for detection, without additional collection of tissue samples, can well replace the existing tissue biopsy and imaging diagnosis modes, and reduce trauma and radiation risks.
- Fig. 1 is an S-plot diagram of the metabolite OPLS-DA provided in Example 1 of the present invention.
- the "local standard substance database” in the present invention refers to the mass spectrometric detection of a large number of related metabolite molecular standards in the present invention, and the collection of mass spectrometry information of these metabolites, thereby forming a localized standard substance database.
- This embodiment provides a method for screening metabolic markers for lung adenocarcinoma diagnosis, comprising the following steps:
- peripheral vein samples from 242 patients with lung adenocarcinoma (lung adenocarcinoma group, including 172 patients with early lung adenocarcinoma) and 150 healthy people (healthy group) were collected from Shanghai Chest Hospital. blood serum.
- lung adenocarcinoma group including 172 patients with early lung adenocarcinoma
- healthy people healthy group
- the diagnostic standard for patients with lung adenocarcinoma is confirmed by postoperative pathology.
- TNM staging patients with stage I and II lung adenocarcinoma were defined as patients with early-stage lung adenocarcinoma.
- step S1 Take out the sample collected in step S1 from the -80°C refrigerator, and thaw it on ice until there are no ice cubes in the sample (subsequent operations are required to be carried out on ice);
- Into a numbered centrifuge tube add 300 ⁇ L pure methanol internal standard extraction solution (containing 100 ppm L-phenylalanine internal standard); vortex for 5 min, let stand for 24 h, and then centrifuge at 12000 r/min, 4 °C for 10 min ; Take 270 ⁇ L of the supernatant and concentrate for 24 hours; then add 100 ⁇ L of acetonitrile and water in a complex solution with a volume ratio of 1:1 for LC-MS/MS analysis. 20 ⁇ L of each sample was mixed to form a quality control sample (QC), which was collected every 15 samples.
- QC quality control sample
- Chromatographic column Waters ACQUITY UPLC HSS T3 C18 1.8 ⁇ m, 2.1mm*100mm; column temperature is 40°C; injection volume is 2 ⁇ L.
- Phase A is an aqueous solution containing 0.1% acetic acid
- phase B is an acetonitrile solution containing 0.1% acetic acid.
- the elution gradient program is: 0min, the volume ratio of phase A to B is 95:5; 11.0min, the volume ratio of phase A to B is 10:90; 12.0min, the volume ratio of phase A to B is 10 :90; 12.1min, the volume ratio of A phase and B phase is 95:5; 14.0min, the volume ratio of A phase and B phase is 95:5V/V.
- Flow rate 0.4mL/min.
- electrospray ionization temperature 500°C
- mass spectrometer voltage 5500V (positive) or -4500V (negative)
- ion source gas I GS I
- gas II GS II
- gas curtain Gas curtain gas, CUR
- collision-induced ionization collision-activated dissociation, CAD
- each ion pair is scanned in MRM mode according to the optimized declustering potential (DP) and collision energy (collision energy, CE).
- DP declustering potential
- CE collision energy
- the samples were analyzed and detected according to the determined liquid chromatography conditions and mass spectrometry conditions: 20% of the samples in the lung adenocarcinoma group and the healthy group were randomly selected, and enhanced ion scanning mass spectrometry (MIM-EPI) and time-of-flight mass spectrometry (TOF) were used.
- MIM-EPI enhanced ion scanning mass spectrometry
- TOF time-of-flight mass spectrometry
- the local standard database was integrated to construct the lung adenocarcinoma serum metabolite database.
- the collected serum samples were analyzed to obtain the original mass spectrometry data of each serum sample.
- the metabolites of the samples were qualitatively and quantitatively analyzed by mass spectrometry. Metabolites of different molecular weights can be separated by liquid chromatography. The characteristic ions of each substance are screened out by the multiple reaction monitoring mode (MRM) of the triple quadrupole, and the signal intensity (CPS) of the characteristic ions is obtained in the detector.
- MRM multiple reaction monitoring mode
- CPS signal intensity
- Use MultiQuant software to open the mass spectrum file of the sample off-machine, preprocess and correct the original mass spectrum data according to the mass-to-charge ratio and retention time, and perform the integration and calibration of the chromatographic peaks.
- the peak area (Area) of each chromatographic peak represents the corresponding substance.
- the repeatability of metabolite extraction and detection can be judged by overlaying and displaying the total ion chromatograms (TIC charts) of different quality control QC samples for mass spectrometry detection and analysis, that is, technical repetition.
- the high stability of the instrument provides an important guarantee for the repeatability and reliability of the data.
- the CV value is the coefficient of variation (Coefficient of Variation), which is the ratio of the standard deviation of the original data to the mean of the original data, which can reflect the degree of dispersion of the data.
- the Empirical Cumulative Distribution Function (ECDF) can be used to analyze the frequency of the CV of substances less than the reference value.
- the proportion of substances with 0.5 is higher than 85%, indicating that the experimental data is relatively stable; the proportion of substances with QC sample CV value less than 0.3 is higher than 75%, indicating that the experimental data is very stable.
- the change of the CV value of the internal standard L-phenylalanine during the detection process was monitored, and the change of the CV value of the internal standard was less than 20%, indicating that the instrument was stable during the detection process.
- the peak area integration data were imported into SIMCA software (Version 14.1, Sweden) for multivariate statistical analysis.
- OPLS-DA orthogonal-partial least squares discriminant
- Ten differential metabolites screened by binary logistic regression forward stepwise method can diagnose and distinguish lung adenocarcinoma patients from healthy people: D-galactose, homocitrulline, N6-acetyl-L-lysine, 4-hydroxy -L-proline, hexadecanedioic acid, guanine, glutamic acid, creatine, alanine, kynuric acid. See Table 3 to Table 5 for specific information on metabolites:
- ROC receiver operating characteristic curve
- Table 7 The AUC value of any differential metabolite combined for the diagnosis of lung adenocarcinoma
- Example metabolic marker combinations are as follows:
- a further preferred combination of metabolic markers is: D-galactose, homocitrulline, and N6-acetyl-L-lysine to construct a model for diagnosing lung adenocarcinoma.
- the AUC value of these three metabolites combined for the diagnosis of lung adenocarcinoma reached 0.925. Under the optimal cutoff value, the sensitivity and specificity were 90.8% and 90.3%, respectively.
- a further preferred combination of metabolic markers is: D-galactose, homocitrulline, N6-acetyl-L-lysine, 4-hydroxy-L-proline, hexadecanedioic acid, and guanine to construct a diagnostic lung gland cancer model.
- the AUC value of these 6 metabolites combined to diagnose benign and malignant pulmonary nodules reached 0.956. Under the optimal cutoff value, the sensitivity and specificity were 94.1% and 93.3%, respectively.
- Table 8 The AUC value of a single metabolite for the diagnosis of early lung adenocarcinoma
- Example metabolic marker combinations are as follows:
- a further preferred combination of metabolic markers is: D-galactose, homocitrulline, and N6-acetyl-L-lysine to construct a model for diagnosing early lung adenocarcinoma.
- the AUC value of these three metabolites combined to diagnose early lung adenocarcinoma reached 0.925. Under the optimal cutoff value, the sensitivity and specificity were 90.8% and 90.3%, respectively.
- a further preferred combination of metabolic markers is: D-galactose, homocitrulline, N6-acetyl-L-lysine, 4-hydroxy-L-proline, hexadecanedioic acid, guanine, constructing an early diagnosis Lung adenocarcinoma model.
- the combined AUC value of these 6 metabolites in the diagnosis of early lung adenocarcinoma reached 0.956. Under the optimal cutoff value, the sensitivity and specificity were 94.1% and 93.3%, respectively.
- Example 2 Validation of diagnostic markers for lung adenocarcinoma
- the subjects of this study included 266 serum samples of patients with lung adenocarcinoma from 2 independent medical centers, including 118 patients with early lung adenocarcinoma; and 149 serum samples of healthy people, which were from the same source as the feature screening samples (150 cases) .
- the diagnostic standard of lung adenocarcinoma is lung adenocarcinoma diagnosed by postoperative pathology; healthy people are healthy people without lung diseases after physical examination. All lung adenocarcinoma patients and healthy samples had no history of any other malignant tumors, no other major systemic diseases, and no chronic medical history of long-term medication.
- patients with stage I and II lung adenocarcinoma were defined as patients with early-stage lung adenocarcinoma.
- the detection and data analysis methods of this example are the same as those of Example 1, and the differential metabolites detected and analyzed are the following 10 kinds: D-galactose, homocitrulline, N6-acetyl-L-lysine, 4-hydroxy - L-proline, hexadecanedioic acid, guanine, glutamic acid, creatine, alanine, kynuric acid for the diagnosis of lung adenocarcinoma.
- These 10 differential metabolites are individually used to diagnose and distinguish between patients with lung adenocarcinoma and healthy people.
- the ability of early lung adenocarcinoma patients and healthy people is relatively strong, and the area under the ROC curve (AUC) is greater than 0.7, which has clinical diagnostic significance;
- AUC area under the ROC curve
- the AUC is further improved, and the AUC value of 10 joint diagnosis of lung adenocarcinoma reaches 0.955.
- the sensitivity and specificity are 91.5% and 93.6%, respectively; the diagnosis of early lung adenocarcinoma
- the AUC of cancer was 0.983, and the sensitivity and specificity were 93.2% and 96.0% at the best cutoff value. See Table 11 to Table 14 for the AUC of a single and any combination of 2 to 9 metabolites used for diagnosis:
- Table 12 The AUC value of any differential metabolite combined for the diagnosis of lung adenocarcinoma
- D-galactose D-galactose, homocitrulline, N6-acetyl-L-lysine, 4-hydroxy-L-proline, hexadecanedioic acid, and guanine were used to construct a model for diagnosing lung adenocarcinoma.
- the AUC value of these 6 metabolites combined to diagnose benign and malignant pulmonary nodules reached 0.931. Under the optimal cutoff value, the sensitivity and specificity were 90.2% and 91.4%, respectively.
- Table 13 The AUC value of a single metabolite for the diagnosis of early lung adenocarcinoma
- Table 14 The AUC value of any differential metabolite combined for the diagnosis of early lung adenocarcinoma
- Metabolic markers D-galactose, homocitrulline, and N6-acetyl-L-lysine were further optimized to construct a model for diagnosing early lung adenocarcinoma.
- the AUC value of these three metabolites combined to diagnose early lung adenocarcinoma reached 0.916. Under the optimal cutoff value, the sensitivity and specificity were 89.3% and 90.1%, respectively.
- This embodiment provides a detection kit, comprising:
- 50% acetonitrile in water can be used as a solvent to dissolve the standards.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Hematology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Electrochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Dispersion Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
La présente invention concerne un marqueur métabolique pour le diagnostic ou la surveillance d'un adénocarcinome pulmonaire, un procédé de dépistage associé et une application de celui-ci. Le système de marqueur métabolique est choisi parmi une ou plusieurs combinaison(s) de D-galactose, d'homocitrulline, de N6-acétyl-L-lysine, de 4-hydroxy-L-proline, d'acide hexadécanedioïque, de guanine, d'acide glutamique, de créatine, d'alanine et d'acide kynurénique. Le marqueur métabolique selon la présente invention peut diagnostiquer avec précision des patients atteints d'un adénocarcinome pulmonaire, peut distinguer des patients atteints d'un adénocarcinome pulmonaire précoce de personnes en bonne santé, présente une sensibilité élevée et une forte spécificité, peut bien remplacer les modes de diagnostic de biopsie tissulaire et d'imagerie existants, et réduit les risques traumatiques et radiologiques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111318756.7 | 2021-11-09 | ||
CN202111318756.7A CN113960215B (zh) | 2021-11-09 | 2021-11-09 | 用于肺腺癌诊断的标志物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023082820A1 true WO2023082820A1 (fr) | 2023-05-19 |
Family
ID=79469627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/118708 WO2023082820A1 (fr) | 2021-11-09 | 2022-09-14 | Marqueur pour le diagnostic d'un adénocarcinome pulmonaire et son application |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113960215B (fr) |
WO (1) | WO2023082820A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117368479A (zh) * | 2023-11-13 | 2024-01-09 | 郑州大学 | 一种用于肺腺癌诊断的生物标志物及检测试剂盒 |
CN118150738A (zh) * | 2024-05-09 | 2024-06-07 | 中国医学科学院阜外医院 | 一种慢性不可预知应激模型的生物标志物及其应用 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113960215B (zh) * | 2021-11-09 | 2024-03-26 | 上海市第一人民医院 | 用于肺腺癌诊断的标志物及其应用 |
CN114778729B (zh) * | 2022-04-20 | 2023-10-27 | 中国医学科学院药用植物研究所云南分所 | 一种运用广泛靶向代谢组学技术鉴别姜黄品种的方法 |
CN114636774B (zh) * | 2022-04-22 | 2024-05-17 | 苏州市疾病预防控制中心 | 一种预测青少年高血压患病风险的生物代谢标志物组合物 |
CN115876991B (zh) * | 2023-03-08 | 2023-06-23 | 中国医学科学院北京协和医院 | 用于肺栓塞诊断的糖链标志物及其应用 |
CN116106534B (zh) * | 2023-04-11 | 2023-06-27 | 南京品生医学检验实验室有限公司 | 生物标志物组合在制备肺癌预测产品中的应用 |
CN117368476B (zh) * | 2023-09-25 | 2024-03-08 | 西安交通大学医学院第一附属医院 | 七种代谢标志物的检测试剂在制备乳腺癌诊断和预后产品中的应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040063120A1 (en) * | 2002-07-10 | 2004-04-01 | The Regents Of The University Of Michigan | Expression profile of lung cancer |
CN101923080A (zh) * | 2010-03-22 | 2010-12-22 | 苏州大学附属第一医院 | 一种肺腺癌血清标志物蛋白质 |
CN108139381A (zh) * | 2015-06-26 | 2018-06-08 | 百奥马克癌症系统公司 | 肺癌检测方法 |
CN108414660A (zh) * | 2018-03-08 | 2018-08-17 | 中国药科大学 | 一组与肺癌早期诊断相关的血浆代谢小分子标志物及其应用 |
CN109725072A (zh) * | 2017-10-27 | 2019-05-07 | 中国医学科学院药物研究所 | 一种基于lc-ms/ms技术的筛查癌症生物标志物的靶向定性定量代谢组学分析方法 |
CN113267586A (zh) * | 2021-04-30 | 2021-08-17 | 上海交通大学医学院 | 嘌呤代谢标志物在制备肺癌分子靶向药物获得性耐药筛查和诊断试剂中的应用 |
CN113960215A (zh) * | 2021-11-09 | 2022-01-21 | 上海市第一人民医院 | 用于肺腺癌诊断的标志物及其应用 |
-
2021
- 2021-11-09 CN CN202111318756.7A patent/CN113960215B/zh active Active
-
2022
- 2022-09-14 WO PCT/CN2022/118708 patent/WO2023082820A1/fr unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040063120A1 (en) * | 2002-07-10 | 2004-04-01 | The Regents Of The University Of Michigan | Expression profile of lung cancer |
CN101923080A (zh) * | 2010-03-22 | 2010-12-22 | 苏州大学附属第一医院 | 一种肺腺癌血清标志物蛋白质 |
CN108139381A (zh) * | 2015-06-26 | 2018-06-08 | 百奥马克癌症系统公司 | 肺癌检测方法 |
CN109725072A (zh) * | 2017-10-27 | 2019-05-07 | 中国医学科学院药物研究所 | 一种基于lc-ms/ms技术的筛查癌症生物标志物的靶向定性定量代谢组学分析方法 |
CN108414660A (zh) * | 2018-03-08 | 2018-08-17 | 中国药科大学 | 一组与肺癌早期诊断相关的血浆代谢小分子标志物及其应用 |
CN113267586A (zh) * | 2021-04-30 | 2021-08-17 | 上海交通大学医学院 | 嘌呤代谢标志物在制备肺癌分子靶向药物获得性耐药筛查和诊断试剂中的应用 |
CN113960215A (zh) * | 2021-11-09 | 2022-01-21 | 上海市第一人民医院 | 用于肺腺癌诊断的标志物及其应用 |
Non-Patent Citations (3)
Title |
---|
"Doctoral Dissertation", 1 May 2019, NANCHANG UNIVERSITY, CN, article YU, JIANGQING: "Exploring the Potential Biomarkers for Diagnosis and Classification of Lung Cancer by Non-Targeting and Targeted Metabonomics", pages: 1 - 88, XP009545602 * |
QIAN, XIANG ET AL.: "Multi-Omics Analysis of Yin Deficiency And Internal Heat Syndrome of Non-Small Cell Lung Cancer Based on System Biology", CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, vol. 36, no. 11, 1 November 2021 (2021-11-01), XP009546360, ISSN: 1673-1727 * |
ZHANG JIN-SHENG: "The Role of Lysine Acetylation of Protein in Lung Cancer And Pulmonary Fibrosis", FUDAN UNIV J MED SCI, vol. 38, no. 4, 1 July 2011 (2011-07-01), pages 287 - 293, XP093066854 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117368479A (zh) * | 2023-11-13 | 2024-01-09 | 郑州大学 | 一种用于肺腺癌诊断的生物标志物及检测试剂盒 |
CN118150738A (zh) * | 2024-05-09 | 2024-06-07 | 中国医学科学院阜外医院 | 一种慢性不可预知应激模型的生物标志物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113960215B (zh) | 2024-03-26 |
CN113960215A (zh) | 2022-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2023082820A1 (fr) | Marqueur pour le diagnostic d'un adénocarcinome pulmonaire et son application | |
WO2023082821A1 (fr) | Marqueur métabolique sérique pour le diagnostic des nodules pulmonaires bénins et malins et son utilisation | |
CN112505228B (zh) | 用于评估受试者心血管疾病风险的代谢标志物组合及其应用 | |
Wang et al. | Investigation and identification of potential biomarkers in human saliva for the early diagnosis of oral squamous cell carcinoma | |
Shen et al. | Developing urinary metabolomic signatures as early bladder cancer diagnostic markers | |
CA2619732C (fr) | Methodes permettant de diagnostiquer les etats pathologiques dus au cancer colorectal et au cancer de l'ovaire | |
WO2023083197A1 (fr) | Marqueur métabolique pour diagnostiquer ou surveiller le cancer du poumon, et son procédé de dépistage et son utilisation | |
CN111562338B (zh) | 透明肾细胞癌代谢标志物在肾细胞癌早期筛查和诊断产品中的应用 | |
Cala et al. | Urinary metabolite and lipid alterations in Colombian Hispanic women with breast cancer: A pilot study | |
CN113960235B (zh) | 生物标志物在制备肺癌检测试剂中的用途和方法 | |
US20170097355A1 (en) | Biomarkers and methods to distinguish ovarian cancer from benign tumors | |
Struck-Lewicka et al. | Analysis of urinary nucleosides as potential cancer markers determined using LC–MS technique | |
WO2013177222A1 (fr) | Biomarqueurs métaboliques pour la détection du cancer du foie | |
Guo et al. | Evaluation of significant features discovered from different data acquisition modes in mass spectrometry-based untargeted metabolomics | |
Liang et al. | Serum metabolomics uncovering specific metabolite signatures of intra-and extrahepatic cholangiocarcinoma | |
CN114924073B (zh) | 结直肠进展期肿瘤诊断标志物组合及其应用 | |
Liu et al. | Free amino acid profiling of gastric juice as a method for discovering potential biomarkers of early gastric cancer | |
Tan et al. | Pharmacometabolomics identifies dodecanamide and leukotriene B4 dimethylamide as a predictor of chemosensitivity for patients with acute myeloid leukemia treated with cytarabine and anthracycline | |
Chen et al. | Targeting amine-and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers | |
CN109946411B (zh) | 用于胸椎黄韧带骨化诊断的生物标记物及其筛选方法 | |
Issaq et al. | Biomarker discovery: study design and execution | |
CN111273023B (zh) | 一种肺腺癌肿瘤标记物蛋白及其应用 | |
Lv et al. | Exploratory study on application of MALDI‑TOF‑MS to detect serum and urine peptides related to small cell lung carcinoma | |
KR20160146102A (ko) | N-당쇄 질량분석을 이용한 대장암 진단방법 | |
Zou et al. | Small molecules as potential biomarkers of early gastric cancer: A mass spectrometry imaging approach |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22891625 Country of ref document: EP Kind code of ref document: A1 |